Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension

Journal of Hypertension

Volumn 22, Issue 4, 2004, Pages 837-846

  Calvo, Carlos ^a   Hermida, Ramón C ^b   Ayala, Diana E ^b   Ruilope, Luis M ^c  

^a Instituto de Salud Carlos III   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Essential hypertension; Telmisartan; Treatment efficacy; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; TELMISARTAN; VALSARTAN;

ACCURACY; ACTIMETRY; ADULT; ANTIHYPERTENSIVE ACTIVITY; AROUSAL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CALCULATION; CIRCADIAN RHYTHM; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT; PATIENT MONITORING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TABLET; TIME; WRIST;

EID: 2142643146     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200404000-00028     Document Type: Article

References (37)

1. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18:797-810.
2. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999; 17:293-302.
3. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-183.
4. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
5. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54:299-311.
6. Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang YT, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19:447-458.
7. Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999; 13:275-281.
8. Lasko BH, Laplante A, Hebert D, Bonnefis-Boyer S. Canadian valsartan study in patients with mild-to-moderate hypertension. Blood Press Monit 2001; 6:91-99.
9. Elliot HL. Trough:peak ratio and twenty-four-hour blood pressure control. J Hypertens 1994; 12(suppl 5):S29-S33.
10. Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker-telmisartan. Blood Press 2001; 10(suppl 1):27-32.
11. Neutel JM. Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other anti-hypertensive drugs. Blood Press Monit 2000; 5(suppl 1):S35-S40.
12. Neutel JM, Klein C, Meinicke TW, Schumacher H. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11:302-309.
13. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16:1123-1132.
14. Bakris G. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens 2002; 4(suppl 1):26-31.
15. O'Brien E, Staessen J. Normotension and hypertension as defined by 24-hour ambulatory blood pressure monitoring. Blood Press 1995; 4:266-282.
16. Anwar YA, Giacco S, McCabe EJ, Tendler BE, White WB. Evaluation of the efficacy of the Omron HEM-737 lntellisense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation. Blood Press Monit 1998; 3:261-265.
17. Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens 2000; 13:262-267.
18. Hermida RC, Calvo C, Ayala DE, Mojón A, López JE. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens 2002; 20:1097-1104.
19. Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Calvo C. Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol Int 2002; 19:461-481.
20. Staessen J, Fagard R, Lijnen P, Thijs L, Vaa Hoof R, Amery A. Ambulatory blood pressure monitoring in clinical trials. J Hypertens 1991; 9(suppl 1):s13-s19.
21. Fernández JR, Hermida RC. Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol Int 1998; 15:191-204.
22. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6:65-70.
23. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16:1685-1691.
24. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers [Letter]. Lancet 1988; 13:397.
25. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, et al. Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003; 42:283-290.
26. Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989; 13:392-400.
27. Madhavan S, Ooi WI, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23:395-401.
28. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JI, Ducimetiere P, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415.
29. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure. A potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32:983-988.
30. Asmar R, Rudnichi A, Blacher J, London GM, Safar ME. Pulse presure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens 2001; 14:91-97.
31. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103:2579-2584.
32. Blacher J, Gasowski J, Staessen JA, Girerd X, This L, Liu L, et al. Pulse pressure - not mean pressure - determines cardiovascular risk in older hypertensive patients. Arch Med 2000; 160:1085-1089.
33. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100:354-360.
34. Hermida RC, Calvo C, Ayala DE, López JE, Domínguez MJ, Covelo M, et al. Incidence of non-dipping pattern of blood pressure in hypertensive patients with and without type II diabetes mellitus. J Hypertens 2003; 21(suppl 4):S214.
35. Palatini P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs. Drugs 1999; 57:713-724.
36. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1:113-119.
37. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21:1291-1298.